About Abivax SA
Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
Abivax SA (ABVX) Stock Score & Signals
Abivax SA (ABVX) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 52 out of 100.
2BB score and signals
Abivax SA’s current 2BB score is 52 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 70 | High |
| Momentum | 34 | Weakening |
| Financial strength | 1 | Very Weak |
| Quality | 79 | Strong |
| Risk | 45 | Moderate (provisional) |
Company facts
| CEO | Marc de Garidel | Hartmut J. Ehrlich |
| Founded | Dec 4, 2013 |
| Employees | 98 |
| 52-week range | $69.81 – $148.83 |
Recent earnings
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-03-22 | — | -1.6422 | — | $2.55M |
| 2026-12-14 | — | — | — | — |
| 2026-09-21 | -2.09 | -1.8258 | $2.54M | $2.55M |